Risk stratification of EGFR+ lung cancer diagnosed with panel-based next-generation sequencing

ISSN
0169-5002
Date Issued
2020
Author(s)
Christopoulos, P.
Kirchner, M.
Roeper, J.
Saalfeld, F.
Janning, M.
Bozorgmehr, F.
Magios, N.
Kazdal, D.
Volckmar, A. L.
Brückner, L. M.
Bochtler, T.
Kriegsmann, M.
Endris, V.
Penzel, R.
Kriegsmann, K.
Eichhorn, M.
Herth, F. J. F.
Heussel, C. P.
Schneider, M. A.
Muley, T.
Meister, M.
Faehling, M.
Fischer, J. R.
Heukamp, L.
Schirmacher, P.
Bischoff, H.
Wermke, M.
Loges, S.
Griesinger, F.
Stenzinger, A.
Thomas, M.
DOI
10.1016/j.lungcan.2020.08.007
Abstract
Panel-based next-generation sequencing (NGS) is increasingly used for the diagnosis of EGFR-mutated non-small-cell lung cancer (NSCLC) and could improve risk assessment in combination with clinical parameters.